ABIONYX Pharma collaborates with CHU de Lille to advance research on **CER-001**, a potential treatment for sepsis. The partnership aims to evaluate the therapeutic’s efficacy in clinical settings. ABIONYX Pharma develops novel antimicrobial solutions targeting severe infections.
ABIONYX Pharma partners with Lille University Hospital’s burn treatment center and ICU to study **CER-001** in severe burn patients at high sepsis risk. The collaboration targets populations vulnerable to sepsis and multi-organ failure due to acute inflammation and immune dysregulation. The drug aims to address critical gaps in treating severe burn complications.
ABIONYX Pharma secures a strategic partnership with AXPLORA to finalize the bioproduction chain for its drug candidate **CER-001**, advancing its potential commercialization. The collaboration establishes critical manufacturing infrastructure for the therapeutic, targeting late-stage development needs. This milestone follows ABIONYX’s focus on scaling production for clinical and regulatory submissions.
Abionyx partners with Olon to develop and commercialize a sepsis treatment. Manufacturing will occur at two Olon facilities in France. The collaboration aims to advance the treatment’s production and market readiness.
